Date: March 2026  | 1. FDA Crackdown on Unapproved Compounded GLP-1 Products

The U.S. FDA issued 30 warning letters to telehealth companies and compounding pharmacies marketing unapproved compounded GLP-1 products (e.g., semaglutide, tirzepatide) with false efficacy claims, threatening product seizures and injunctions for non-compliance.

Date: March 2026  | 2. NICE Approves Wegovy for Cardiovascular Risk Reduction

The UK’s NICE approved Novo Nordisk’s Wegovy for cardiovascular risk reduction, expanding its indication beyond obesity and weight management.

Date: March 6, 2026 | 3. Pfizer Enters China Obesity Market with Sciwind-partnered Ecnoglutide

Pfizer secured NMPA approval for Xianweiying (ecnoglutide) in China, marking its entry into the Chinese obesity market, following a $495 million deal with Sciwind Biosciences for China marketing rights.

Date: March 2026  | 4. Pinnacle Medicines Raises $89M Series B for Oral Peptide Pipeline

U.S.-China backed Pinnacle Medicines raised $89 million in Series B funding to advance its oral peptide pipeline, focusing on cardiometabolic and immunology indications.

Date: March 2026  | 5. Kailera Plans IPO to Fund Hengrui’s GLP-1 Global Development

Kailera Therapeutics, holding ex-China rights to four Hengrui GLP-1 drugs, plans an IPO to fund global pipeline development, with lead candidate ribupatide in global Phase 3.

Date: March 7, 2026 | 6. Hansoh/Regeneron’s Olatorepatide Posts Phase 3 Efficacy

Hansoh Pharma reported Phase 3 data for olatorepatide (GLP-1/GIP agonist) with up to 19.3% weight loss at 48 weeks, comparable to Lilly’s Zepbound, with superior GI safety. Regeneron plans a global Phase 3 program in 2026.

Date: March 2026  | 7. Structure’s Oral GLP-1 Aleniglipron Achieves 16.3% Weight Loss

Structure Therapeutics reported Phase 2 data for oral GLP-1 aleniglipron, with up to 16.3% placebo-adjusted weight loss at 44 weeks, planning Phase 3 in H2 2026.

Date: March 2026  | 8. Eli Lilly’s Retatrutide Shows Positive Phase 3 Data in T2DM

Lilly’s triple GLP-1/GIP/glucagon agonist retatrutide delivered 16.8% weight loss and 1.9% A1C reduction in Type 2 diabetes patients at 40 weeks, with an obesity NDA planned by end-2026.

Date: March 2026  | 9. Ascletis’ Ultra-Long-Acting GLP-1 ASC30 Posts Positive Phase 2 Data

Ascletis Pharma’s ultra-long-acting injectable GLP-1 ASC30 (monthly-then-quarterly dosing) showed positive Phase 2 data with sustained weight loss.

Date: March 2026  | 10. Merck’s Oral Peptide PCSK9 Inhibitor Enlicitide Shows Strong Phase 3 Data

Merck’s oral macrocyclic peptide PCSK9 inhibitor enlicitide reduced LDL-C by 64.6% at Day 56, with an imminent FDA filing.

Date: March 6, 2026 | 11. Zealand/Roche’s Petrelintide Achieves Phase 2 Weight Loss

Zealand Pharma and Roche reported Phase 2 data for weekly injectable amylin analog petrelintide, with up to 10.7% weight loss, offering an alternative for GLP-1-intolerant patients.

Date: March 2026  | 12. Preclinical Study Expands GLP-1’s Cardiovascular Potential

GLP-1 agonists were found to relax constricted blood vessels and improve post-myocardial infarction “no-reflow” in rodents, expanding their potential to cardiovascular care.

Date: March 20, 2026 | 13. Semaglutide Core Patent Expires in China

Novo Nordisk’s semaglutide core compound patent expired in China on March 20, 2026, with over 10 domestic biosimilar applications near approval.

Date: March 6, 2026 | 14. China Approves World’s First cAMP-Biased GLP-1 Ecluglutide

China’s NMPA approved Sciwind/Pfizer’s ecluglutide (Xianweiying®), the world’s first cAMP-biased GLP-1, for weight management, with 15.4% average weight loss over 48 weeks.

JYMed peptide Technology Co., Ltd.

A leading peptide solutions provider